Citations

Clear

4610 citation(s) found for "Lu, Brian".

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development
Garg, Shivani , Hartel, Izzy, Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Rovin, Brad H. , Turner, Amy S. , Williams, Bené, Ung, Brian , Bhavsar, Hiya, Gore‐Massy, Monique , Pulido, Nahirannette, Guerrero, N Hernandez, Smith, Natalie, Machua, Wambui, Hiraki, Linda T. , Rovin, Brad H , Turner, Amy S , Hiraki, Linda T , Duarte-García, Alí , Garg, Shivani , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Werth, Victoria P. , Mustafa, Reem A , Williams, Bené, Pulido, Nahirannette, Guerrero, Natacha, Son, Mary Beth F.

Mayo Clinic

Arthritis Care & Research | November 3, 2025 | Volume: 78 | Issue: 7 | Pages: 925-935

10.1002/acr.25693 | PMID 41182325 Get It

Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN) and 2025 SLE screening, treatment guidelines. Methods We completed a cross‐sectional qualitative study using content analysis of two Patient Panel meetings for the ACR LN and SLE guidelines. Key themes were presented by Patient Panel representatives during Voting Panel Meetings along with evidence for each recommendation, to ensure comprehensive discussions and align treatment recommendations with patients’ priorities and values. Results Nineteen people (90% women) with diagnoses of SLE and/or LN participated in the Patient Panels and 17 consented to use their feedback for analysis. Thematic analysis of their discussions revealed nine patient‐reported key themes in three domains: (1) treatment and monitoring of LN and SLE: medication side effects, daily function, treatment goals, and monitoring and screening; (2) clinical communication: strategies to optimize communication and provider and structural impediments to effective communication; and (3) improving transparency and information sharing: clinical trial participation, and medical costs and insurance coverage. These themes were actively incorporated into discussions during the Voting Panels for the ACR LN and SLE guidelines. Conclusion This work supported the integration of patient experiences in the clinical practice guideline development process and aligned recommendations with real‐world patient experiences and priorities, thereby enhancing the clinical applicability of the ACR LN and SLE guidelines. image
Mental Health Outcomes in Adolescents/Young Adults Following Reduction Mammaplasty: A Systematic Review and Single-arm Meta-analysis
Oliveira, Juliana Almeida , Mattey, Luke , White, Ava G., McNamara, Catherine T., Labow, Brian I. , Kreutz‐Rodrigues, Lucas , Eskandar, Karine Oliveira

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 3, 2025 | Volume: 13 | Issue: 11 | Pages: e7245

10.1097/gox.0000000000007245 | PMID 41190099 Get It

Background: Macromastia causes significant physical and psychological distress in adolescents. Although reduction mammaplasty alleviates these symptoms, the mental health impact of macromastia in younger populations remains underexplored. This systematic review and meta-analysis aimed to evaluate mental health and quality of life outcomes in adolescents/young women undergoing reduction mammaplasty. Methods: A systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted from inception to September 2024. Studies reporting mental health or quality of life outcomes through the BREAST-Q, Short Form-36, Rosenberg Self-Esteem Scale, and Eating Attitudes Test were included. Odds ratios and mean difference with 95% confidence intervals were pooled using a random-effects model. Heterogeneity was assessed with I 2 statistics. The Risk of Bias in Nonrandomized Studies of Interventions tool was used to assess study quality. Meta-analysis was performed on 4 BREAST-Q domains. Results: Of 701 articles identified, 8 observational studies involving 660 patients were included. Pooled BREAST-Q scores postsurgery showed significant improvements across all 4 domains. Improvement in Short Form-36, Rosenberg Self-Esteem Scale, and Eating Attitudes Test scores was noted in individual studies, though meta-analysis was limited by incomplete data. Conclusions: These results indicate that reduction mammaplasty significantly improves the physical, psychosocial, and sexual well-being of adolescents/young women with macromastia.
Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Sperry, Brett W. , Masri, Ahmad , Grogan, Martha , Mooney, Deirdre, Akinboboye, Olakunle O., Drachman, Brian, Nativi-Nicolau, José , Tamby, Jean‐François, Castaño, Adam , Fox, Jonathan C. , Cheng, Richard K. , Cheng, Richard , Sperry, Brett W , Kobayashi, Masatake , Chen, Christopher S. , Cheng, Richard , Judge, Daniel P. , Cappelli, Francesco

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4363872 Get It

Background: Atrial fibrillation (AF) significantly impacts quality of life (QoL) and is often observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis achieves near-complete (≥90%) transthyretin (TTR) stabilization and is approved in the USA, the UK, Europe and Japan for the treatment of ATTR-CM in adults. In the phase 3 ATTRibute-CM study (NCT03860935), acoramidis treatment significantly reduced the time to all-cause mortality (ACM) or first cardiovascular-related hospitalization (CVH) at Month 30, and resulted in improved 6-minute walk distance (6MWD), Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) scores and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels relative to placebo. The clinical efficacy of acoramidis has not yet been reported in patients with ATTR-CM and with an AF or atrial flutter (AFL) diagnosis at baseline. Research Question: How does acoramidis treatment affect ACM or first CVH, 6MWD, KCCQ-OS scores, and NT-proBNP levels at Month 30 in participants with ATTR-CM with or without AF/AFL diagnosis at baseline? Methods: The ATTRibute-CM study design has been previously published. This post hoc analysis included participants in the modified intention-to-treat population (N=611) grouped by AF/AFL diagnosis at baseline (defined as recorded AF medical history or the presence of AF or AFL on an ECG at enrollment). The rate of ACM or first CVH at Month 30 was compared between groups using a stratified Cox proportional hazards model. Changes from baseline to Month 30 in 6MWD, KCCQ-OS scores and NT-proBNP levels were summarized descriptively. Results: Overall, 62.8% (384/611) of participants had an AF/AFL diagnosis at baseline (acoramidis: 255/409, placebo: 129/202). These participants had lower mean 6MWD and KCCQ-OS scores and higher median NT-proBNP levels than those without AF/AFL diagnosis at baseline. Treatment with acoramidis reduced ACM or first CVH, slowed the decline in 6MWD and KCCQ-OS scores and blunted the rise in NT-proBNP compared with placebo, regardless of AF/AFL diagnosis at baseline ( Table ). Conclusions: Acoramidis improved clinical outcomes (ACM, CVH), functional status, QoL and NT-proBNP levels relative to placebo in participants with ATTR-CM, regardless of AF/AFL diagnosis at baseline.
Abstract Sun705: Comparison of 5-Year Neurologically Intact Survival Between an Automated Head Up CardiopulmonaryResuscitation Registry and a National Cardiac Arrest Registry
Moore, Johanna , Bachista, Kerry, Salverda, Bayert, Wittmer, Jeff, White, Shaun, Holley, Joe , Cole, J. W., Emanuelson, Lauren, Goodloe, Jeffrey M. , Cox, Matthew, Gomes, Darrin, Siegel, Lewis, Williamson, Chris T., Holloway, Christopher, Sposeto, Tony, Carter, Mark, Hunt, Nathaniel , Poorzand, Pouria, DeVries, R., Cole, Jerome, Davis, Brian, Reynolds, James, Gomes, Darrin, Williamson, Chris, Crawford, William, Carter, Mark, Duval, Sue , Poorzand, Pouria, Debaty, Guillaume P.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.sun705 Get It

Background: Pre-clinical animal studies have demonstrated improved cerebral blood flow and neurological survival with Automated Head Up Position (AHUP) cardiopulmonary resuscitation (CPR) as compared to flat conventional (C) CPR. AHUP CPR consists of 1) automated head and thorax elevation 2) active compression decompression CPR and 3) an impedance threshold device. Subsequently, observational propensity-matched studies of out-of-hospital cardiac arrest (OHCA) patients demonstrated a time-dependent association between survival with intact neurological function (SNF) and application of AHUP CPR. However, comparison of AHUP CPR outcomes with contemporaneous C-CPR controls is lacking. Hypothesis: Use of AHUP CPR for OHCA by first responder agencies will demonstrate a higher incidence of SNF compared to C-CPR outcomes from a national registry Methods: Data from the previous 5 years (2020-2024) from an AHUP-CPR Registry comprised of OHCA patients routinely treated by first responders with AHUP CPR were compared with data from the Cardiac Arrest Registry to Enhance Survival (CARES). Patient demographics, arrest characteristics, ROSC, SHD, and SNF were recorded. SNF was defined as a Cerebral Performance Category 1 or 2 at hospital discharge. A two-sample test of proportions was used for outcome comparisons. Results: Nine AHUP registry sites (MN, FL, TN, IL, OK, VA, AL, IA, MI) were included. Summary 5-year demographics (Table 1) and clinical outcomes (Table 2) are presented. For 2020-2024 AHUP sites, the average time (mm:ss, SD) from 9-1-1 call to start of CPR was 9:09 (4:37) and time to start of AHUP CPR was 12:46 (5:57). The AHUP registry had a higher 5-yr incidence of SNF versus the CARES registry (difference 2.8%, 95% CI 1.8-3.8, p < 0.00001). This difference was consistent year over year (Figure 1). Secondary outcomes of sustained return of spontaneous circulation and survival to hospital discharge in the AHUP registry were also significantly higher than CARES registry data (Table 2). Conclusions: Over a 5-year period, an unadjusted analysis of aggregate data from two OHCA patient registries demonstrated that the incidence of survival with intact neurological function was higher in patients treated with AHUP CPR as part of first responder care versus patients treated with more conventional CPR methods.
Abstract 4352628: Time-Sensitive Cardiovascular Risk After COVID-19: A Population-Based Study Across Variant Eras
Gersh, Bernard, Shapiro, Brian P. , McLeod, Christopher , Niekerk, Christoffel J. van , Kiernan, Jack, Kafil, Tahir S , Bois, John P. , Howick V, James F , Scott, Christopher G. , Chamberlain, Alanna M. , Taylor, Bryan J. , Fairweather, DeLisa , Raphael, Claire E. , Kiernan, Jack, Cooper, Leslie T.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4352628 Get It

Introduction: Cardiovascular risks following SARS-CoV-2 infection are incompletely defined. We evaluated evolving cardiovascular outcomes across COVID-19 variant eras using a large community-based cohort to inform risk stratification and clinical care. Methods: We conducted a retrospective cohort study of 162,471 adults with COVID-19 between March 2020 and December 2023 using the Rochester Epidemiology Project. Patients were stratified by variant era (Pre-Delta, Delta, and Omicron). Cardiovascular outcomes included major adverse cardiovascular events (MACE: myocardial infarction, stroke, death), ischemic and inflammatory heart disease, thrombotic events, and dysrhythmias. Diagnoses were identified using ICD-10 codes and validated in a subset. Cumulative incidence was estimated using Kaplan-Meier and competing risk models. Cox proportional hazards regression was used to assess differences by era and age. Results: MACE occurred in 4,922 patients, primarily in those ≥80 (2-year incidence: 17%). Event rates peaked within 30 days post-infection, with marked variation by variant. In patients ≥80, 30-day MACE risk was highest in the Pre-Delta (HR 3.85; 95% CI, 3.14–4.71) and Delta (HR 2.72; 95% CI, 2.13–3.47) eras versus Omicron. After 30 days, event rates fell and era differences narrowed. Thrombotic events (n=2,090; 1.4%) decreased across eras. Ischemic and inflammatory heart disease rates were stable. Myocarditis/pericarditis were rare (0.1%) without age trends. Dysrhythmias affected 6,765 patients (2-year incidence: 4.9%) and rose with age (2.0% in <40 vs. 19.9% in ≥80). Within 30 days, risk was higher in the Pre-Delta and Delta eras for age ≥40, especially ≥80 (Delta HR 3.08; 95% CI, 2.08–4.56) and 60–79 (HR 2.23; 95% CI, 1.75–2.85). Among those 40–59, Delta posed the highest risk (HR 2.74; 95% CI, 1.94–3.86 vs. Pre-Delta HR 1.77; 95% CI, 1.26–2.49). No differences were observed in <40. Beyond 30 days, risk converged across variants. Conclusion: Cardiovascular risk after SARS-CoV-2 infection was concentrated in the first 30 days, with attenuation thereafter. While MACE and thrombotic event rates declined over time, early dysrhythmia risk varied by variant and age, especially in older adults. These findings define a time-sensitive, variant-specific risk window and support short-term, risk-stratified post-COVID monitoring. This work informs targeted follow-up protocols by infection era and age, with implications for quality improvement, resource use, and equitable care.
Abstract 4367120: Impact of Aortic Valve Calcification on Functional Valve Area and Cardiac Structure and Function in a Phase 2 Trial of Ataciguat
Moore, Liz, Edelberg, Jay M. , Rı́o, Carlos del , Abbas, Cheryl , Michelena, Héctor I. , Pibarot, Phillippe , Moore, Liz, Li, Wanying, Wu, Peiwen, Rio, Carlos del, Miller, Jordan D. , Lindman, Brian R.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4367120 Get It

Background: Calcific aortic valve stenosis (CAVS) is characterized by the progressive accrual of aortic valvular calcium (AVC), resulting in impaired valvular compliance and mechanics and impaired cardiac function leading to heart failure (HF). In a phase 2 trial of 23 patients with moderate CAVS, ataciguat (ATA), a soluble guanylate cyclase activator, relative to placebo slowed the deposition of AVC, decreases in aortic valve area (AVA; by continuity equation), and increases in diastolic dysfunction and left ventricular (LV) mass. ATA may have other favorable effects on ventricular, valvular, and/or vascular pathophysiology relevant to patients with CAVS. Hypothesis: We hypothesized that slowing the rate of AVC deposition is associated with improvements in valvular compliance and in measures of cardiac structure and function. Methods: A phase 2 study randomized patients with moderate CAVS 1:1 to receive ATA 200 mg/day or placebo for up to 12 months (NCT02481258). The primary endpoint was change in AVC assessed by cardiac CT, and measures of aortic valve function and cardiac structure and function were also assessed. AVA was calculated by the Modified Gorlin (Hakki) equation to additionally assess valvular compliance. Correlations between AVC, AVA, and other measures of cardiac structure and function were assessed by exploratory linear mixed models. Results: Changes in AVC from baseline were negatively correlated with changes in AVA (slope = −0.0002 [95% CI −0.0004, 0.0001]; Figure 1), such that patients with the least AVC deposition had minimal changes in AVA. Reciprocally, changes from baseline in AVA were positively correlated with changes in cardiac output (CO; slope = 0.16 [95% CI 0.13, 0.18]; Figure 2). Treatment with ATA, compared with placebo, was associated with improvements in systolic function. Changes in AVC deposition correlated with changes in CO (slope = −0.0007 [95% CI −0.0021, 0.0008]; Figure 3), and measured improvements in CO were generally more observed in patients with less of an increase in AVC, which were more frequently observed in those treated with ATA compared with placebo. Conclusions: These data suggest that slowing the rate of AVC deposition with ATA may result in improvements in CO through improved myocardial function and valvular compliance. Larger controlled trials are needed to assess such favorable myocardial/valvular effects that may help to preserve functional capacity and slow progression to HF.
Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL
Anderson, Daniela R., Gangaraju, Radhika , Sedhom, Wafik G., Hamulyák, Eva N. , Wang, Tzu‐Fei , O’Dwyer, Kristen M. , Muthiah, Chandrasekar, Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Dinner, Shira, Biemond, Bart J. , Goldberg, Leah, Kapadia, Anjani , Levavi, Hannah , Bar‐Natan, Michal , Hyfte, Grace Van , Bansal, Karan, Gerrits, Anke M., Litzow, Mark R. , Luger, Selina M. , Wolach, Ofir , Shomali, William , Stock, W, O'Dwyer, Kristin , Liedtke, Michaela , Badar, Talha , Shimony, Shai , Robinson, Renana , Sanfilippo, Kristen , Derkach, Andriy , Biemond, Bart J , Levavi, Hannah , Carrier, Marc , Fulcher, Jill , Litzow, Mark R. , Luskin, Marlise R , Wolach, Ofir , Shomali, William , Zwicker, Jeffrey I , Carney, Brian J. , Derkach, Andriy , Nemirovsky, David , Carrier, Marc , Murthy, Guru Subramanian Guru , Stock, Wendy, Leader, Avi

Mayo Clinic

Blood Advances | October 31, 2025 | Volume: 10 | Issue: 3 | Pages: 593-603

10.1182/bloodadvances.2025017862 | PMID 41170879 Get It

Abstract The incidence of venous thromboembolism (VTE) in patients with acute lymphoblastic leukemia (ALL) receiving asparaginase-based induction is high despite primary thromboprophylaxis. Our aim was to derive and externally validate a VTE risk prediction model in patients with ALL receiving asparaginase-based induction. We conducted a multicenter retrospective cohort study of patients (aged ≥18 years) with newly diagnosed ALL receiving asparaginase-based induction. The derivation and external validation cohorts included 306 and 94 patients, respectively. Primary outcome was VTE at any site. A cause-specific Cox proportional hazards model stratified by thromboprophylaxis and center was performed to identify VTE risk factors in the derivation cohort. A risk prediction model for VTE at 30 days was derived using variables with P value &lt; .05 in the multivariable model and was tested in the validation cohort. VTE risk factors on multivariable analysis in the derivation cohort included D-dimer ≥1 μg fibrinogen equivalent unit per mL (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.07-6.5) and hemoglobin (HR for each 1 g/dL increment, 1.19; 95% CI, 1.06-1.34) at ALL diagnosis. A VTE risk score based on these variables distinguished between a 4% (95% CI, 0.72-12) and 20% (95% CI, 14-27) 30-day cumulative incidence of VTE in the derivation cohort, with similar findings in the validation cohort (area under the curve, 0.56). The negative predictive value for VTE at 30 days was 96% and 93% in the derivation and validation cohorts, respectively, and the positive predictive value was 20% in both. We derived and validated a model using D-dimer and hemoglobin, which stratifies VTE risk in patients with ALL receiving asparaginase-based induction.
Proton Beam vs Intensity-Modulated Radiotherapy in Olfactory Neuroblastoma
Tang, Anthony , Krippaehne, Elise , Roozdar, Pooya, Goetschel, Kaitlin , Champagne, Pierre‐Olivier , Fernandez‐Miranda, Juan C. , Gardner, Paul , Hwang, Peter H. , Patel, Zara M. , Celda, María Peris, Sanusi, Olabisi , Snyderman, Carl H., Thorp, Brian D. , Zenonos, Georgios A. , Zwagerman, Nathan T. , Wang, Eric W., Olson, Brennan , Patel, Zara , Hwang, Peter H , Adida, Samuel , Donohue, Jack K. , Gago, Guilherme , Almeida, João Paulo , Nayak, Jayakar V. , Patel, Chirag, Pinheiro‐Neto, Carlos , Routman, David M. , Snyderman, Carl H , Gompel, Jamie J. Van , Wilke, Christopher , Wang, Eric W , Geltzeiler, Mathew , Choby, Garret

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 30, 2025 | Volume: 152 | Issue: 1 | Pages: 60

10.1001/jamaoto.2025.3816 | PMID 41165699 Get It

Importance Adjuvant radiotherapy can improve locoregional control and survival in patients with olfactory neuroblastoma (ONB), particularly with advanced-stage and histologic-grade disease. Standard radiotherapy treatment is with intensity-modulated radiotherapy (IMRT). Proton beam radiotherapy (PBRT) provides theoretical advantages in greater sparing of dose to uninvolved organs at risk. Objective To investigate if there are differences in the effectiveness and radiation treatment–related adverse events (RTAEs) between adjuvant IMRT and PBRT for patients with ONB. Design, Setting, and Participants This propensity score–matched cohort study included patients with ONB treated between February 2005 and April 2021 with either IMRT or PBRT at 9 academic tertiary care centers in North America. Patients were matched 1:2 based on age, modified Kadish stage, and Hyams grade. Data were analyzed from July 2024 to January 2025. Exposure Adjuvant IMRT or adjuvant PBRT. Main Outcomes and Measures Local recurrence-free survival (RFS), any RFS, and overall survival (OS). RTAEs, ie, grade 2 events or higher based on Common Terminology Criteria for Adverse Events, were recorded for both modalities. Results Of 54 included patients, 27 (50%) were female, and the mean (SD) age was 46.2 (15.4) years. A total of 18 were treated with PBRT and 36 were treated with IMRT. Most patients had modified Kadish stage C disease (33 of 54 [61%]), and 24 patients (44%) had Hyams grade III or IV disease. The RTAE rate was 20% (8 of 40); IMRT had a rate of 21% (6 of 29), and PBRT had a rate of 18% (2 of 11). The difference in the point estimates for 10-year RFS showed a potential clinical benefit favoring IMRT, although the wide confidence interval indicates uncertainty (10-year RFS: IMRT, 63.3%; 95% CI, 44.6-89.8; PBRT, 37.8%; 95% CI, 14.2-100; difference, 25.5 percentage points; 95% CI, −17.6 to 68.6). There were no clinically meaningful differences in 10-year local RFS (IMRT, 75.6%; 95% CI, 59.8-95.4; PBRT, 72.7%; 95% CI, 45.2-100; difference, 2.9 percentage points; 95% CI, −35.9 to 41.7) or 10-year OS (IMRT, 61.8%; 95% CI, 42.8-89.1; PBRT, 57.1%; 95% CI, 24.3-100; difference, 4.7 percentage points; 95% CI, −49.2 to 58.6), although wide confidence intervals indicate considerable uncertainty. Conclusions and Relevance Due to the imprecision of estimates, no definitive conclusions can be made regarding the comparative effectiveness of IMRT vs PBRT for patients with ONB. These preliminary data may inform the design of appropriately powered prospective studies evaluating the efficacy of PBRT vs IMRT in this population.
Comparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease
Wisch, Julie K. , Christian, Bradley T. , Schultz, Stephanie A. , Millar, Peter R , Ryan, Natalie S. , Belder, Christopher R S , Chrem, Patricio, Day, Gregory S. , Murphy, Mei, Roh, Jee Hoon , Xiong, Chengjie , Wang, Guoqiao , Li, Yan , Schindler, Suzanne E., Jack, Cliff R, Networ, the Dominantly Inherited Alzheimer, Jack, Cliff, Day, Gregory S , Roh, Jee Hoon , Wisch, Julie K , McKay, Nicole S. , Zammit, Matthew D. , Cash, David M. , Cruchaga, Carlos , Ibanez, Laura , Jucker, Mathias , Yakushev, Igor , Murphy, Mei, Llibre‐Guerra, Jorge J. , Aguillon, David , Xiong, Chengjie , Schindler, Suzanne E. , McDade, Eric , Bateman, Randall J. , Benzinger, Tammie L.S. , Ances, Beau M. , Networ, the Dominantly Inherited Alzheimer, Betthauser, Tobey J. , Gordon, Brian A.

Mayo Clinic

Alzheimer's & Dementia | October 25, 2025 | Volume: 21 | Issue: 10 | Pages: No page available

10.1002/alz.70812 | PMID 41137622 Get It

Abstract INTRODUCTION Preclinical Alzheimer's disease (AD) can be described relative to biomarker positivity onset time. METHODS We estimated time from amyloid positivity (A+) using sampled iterative local approximation (SILA) in a longitudinal autosomal dominant AD (ADAD) sample ( N = 379) with amyloid positron emission tomography. We compared (1) predicted age at A+ to imputed age, (2) estimated age at A+ to estimated age at symptom onset, and (3) variance in cognitive performance explained. RESULTS Mean error between imputed and SILA‐estimated age at A+ ( N = 26) was 1.15 years. Age at A+ explained 39% of estimated years to symptom onset (EYO) variance. Time from A+ explained 19% of cognitive composite variance and 14% of Clinical Dementia Rating Sum of Boxes CDR‐SB variance; EYO explained 43% and 57%, respectively. DISCUSSION SILA estimates A+ age in ADAD with reasonably good accuracy. SILA‐estimated time from A+ describes the start of pathology, but the time from A+ onset to symptoms is variable in ADAD and better described by EYO. Highlights Amyloid chronicity predicts a 14‐year preclinical AD phase in ADAD. SILA accurately estimates age at A+ (MAE < 2 years). EYO outperforms chronicity in predicting symptom onset. APP mutation carriers show atypical amyloid accumulation. Chronicity models help reveal AD heterogeneity in preclinical stages.
3498 Non-invasive neuromodulation for the treatment of drug-resistant epilepsy: systematic review and meta-analysis investigating efficacy, safety, and optimal stimulation parameters
Premaratne, Sayumi , Hamer, Ryan P. , O’Brien, Terry, Zoghi, Maryam , Antonic‐Baker, Ana , Chen, Zhibin ZC , Chen, Leo , Major, Brendan P. , Thomas, Elizabeth H. X. , Kwan, Patrick , O’Brien, Terry, Lundstrom, Brian N. , Simpson, Hugh D.

Mayo Clinic

Poster Abstracts | October 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: A27.2-A27

10.1136/bmjno-2025-anzan.72 Get It